Sugi Predict

Sugi Predict / Compounds / SCHEMBL183025

SCHEMBL183025

SCHEMBL183025

FC(F)c1ccccc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IDO1 P14902 1/20 0.42
▸ TDO2 P48775 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.38
▸ HTT P42858 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ OPRL1 P41146 2/20 0.34
▸ CYP2C19 P33261 3/20 0.33
▸ CYP3A4 P08684 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ CA1 P00915 2/20 0.32
▸ CA2 P00918 2/20 0.32
▸ CA4 P22748 1/20 0.32
▸ CA6 P23280 1/20 0.32
▸ TDP1 Q9NUW8 1/20 0.32
▸ CFTR P13569 2/20 0.32
▸ OPRM1 P35372 1/20 0.32
▸ OPRD1 P41143 1/20 0.32
▸ OPRK1 P41145 1/20 0.32
▸ CYP2C9 P11712 2/20 0.31
▸ GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29498705 1.00 IDO1 (0.42) IDO1TDO2ALDH1A1HTTMAPK1
SCHEMBL23430140 0.82 HTR3E (0.33) IDO1TDO2ALDH1A1HTTOPRL1
SCHEMBL15973428 0.79 HTT (0.42) IDO1TDO2ALDH1A1HTTMAPK1
SCHEMBL1538924 0.78 GABRA1 (0.35) IDO1TDO2ALDH1A1HTTMAPK1
SCHEMBL29861488 0.77 IDO1 (0.31) IDO1TDO2
SCHEMBL29525404 0.77 KDM1A (0.31) IDO1TDO2
SCHEMBL23326396 0.77 IDO1 (0.31) IDO1TDO2
SCHEMBL16636835 0.77 KDM1A (0.31) IDO1TDO2
SCHEMBL4087851 0.77 IDO1 (0.45) IDO1TDO2ALDH1A1HTTMAPK1
SCHEMBL21132602 0.75 ALDH1A1 (0.37) ALDH1A1MAPK1CYP3A4CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 225 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4059610-A Process for preparing isocyanic acid derivatives KAO SOAP CO., LTD. (JA) 1977-11-22 — — US claimed
US-12630566-B2 KRas G12D inhibitors Mirati Therapeutics, Inc. (US) 2026-05-19 — — US disclosed
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 — — US disclosed
US-12435078-B2 Pyridazinones and methods of use thereof GFB (ABC), LLC (US) 2025-10-07 — — US disclosed
US-20250275952-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS MYOKARDIA INC (US) 2025-09-04 — — US disclosed
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 — — EP disclosed
EP-3870577-B1 INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION VIIV HEALTHCARE UK NO 5 LTD (GB) 2025-03-19 — — EP disclosed
EP-4512811-A1 OXAZEPINE DERIVATIVE Teijin Pharma Limited (JP) 2025-02-26 — — EP disclosed
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF Pipeline Therapeutics, Inc. 2025-01-30 — — US disclosed
EP-4474017-A2 NEW HETEROCYCLIC COMPOUNDS F. Hoffmann-La Roche AG (CH) 2024-12-11 — — EP disclosed
US-20080167305-A1 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED 2008-07-10 — — US disclosed
CN-101068794-A Quinazolines useful as modulators of ion channels VERTEX PHARMA (US) 2007-11-07 — — CN disclosed
WO-2007058989-A2 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 — — WO disclosed
WO-2007058989-A2 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-05-24 — — WO disclosed
EP-1784393-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS Vertex Pharmaceuticals Incorporated (US) 2007-05-16 — — EP disclosed
WO-2006028904-A9 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMA (US) 2006-06-22 — — WO disclosed
WO-2006028904-A1 QUINAZOLINES USEFUL AS MODULATORS OF ION CHANNELS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-03-16 — — WO disclosed
CN-1220666-C Monomer containing electron drawing group and electron donating group and polymer and proton conductive membrane containing same JSR CORP (JP) 2005-09-28 — — CN disclosed
CN-1379009-A Monomer containing electron drawing group and electron donating group and polymer and proton conductive membrane containing same JSR CORP (JP) 2002-11-13 — — CN disclosed
US-4059610-A Process for preparing isocyanic acid derivatives KAO SOAP CO., LTD. (JA) 1977-11-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12630566-B2 KRas G12D inhibitors KRAS, NRAS, HRAS IDO1 4512/4885TDO2 4498/4885ALDH1A1 1816/4885
US-20250275952-A1 4-METHYLSULFONYL-SUBSTITUTED PIPERIDINE UREA COMPOUNDS TNNI3, UMPS, TNNT2 IDO1 4281/4885TDO2 4502/4885ALDH1A1 3067/4885
US-20250034110-A1 LPAR1 ANTAGONISTS AND USES THEREOF LPAR1, LPAR2, LPAR3 IDO1 2730/4885TDO2 4769/4885ALDH1A1 1523/4885
US-12435078-B2 Pyridazinones and methods of use thereof PDXK, ATP6V1B1, REN IDO1 952/4885TDO2 351/4885ALDH1A1 649/4885
US-20080167305-A1 QUINAZOLINES USEFUL AS MODULATORS OF VOLTAGE GATED ION CHANNELS KCNQ1, KCNQ2, KCNQ5 IDO1 2340/4885TDO2 2811/4885ALDH1A1 2703/4885
US-20260116891-A1 Oxazepin Derivative HCRTR2, HCRTR1, OXTR IDO1 845/4885TDO2 1700/4885ALDH1A1 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.